How long is the follow up for cll11?

Anticipated time on study treatment is >6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.

Who are the sponsors of the cll11 trial?

In the US, this trial is sponsored/managed by Genentech. Protocol BO21004 is divided into 3 separate Unique Protocol IDs for reporting results on because there are 3 separate primary analyses conducted at different time-points.

Which is better for CLL obinutuzumab or chlorambucil?

Treatment with obinutuzumab–chlorambucil, as compared with chlorambucil alone, prolonged overall survival (hazard ratio for death, 0.41; 95% CI, 0.23 to 0.74; P=0.002).

Are there any patients with CD20 positive CLL?

In this open-label, three-group study, we enrolled patients with CD20-positive CLL that was diagnosed according to the criteria of the International Workshop on Chronic Lymphocytic Leukemia. 21 Previously untreated patients requiring treatment (i.e., those with Binet stage C or symptomatic disease) were included.

What are the new features of Android 11?

Experience what Android 11 has to offer on devices made for the latest and greatest. And there’s so much more. From security enhancements to easier ways to get work done, Android 11 has something for everyone. Voice Access Intuitive labels on apps help you control and navigate your phone, all by speaking out loud.

Which is better for CLL obinutuzumab or rituximab?

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL).